poziotinib
poziotinib: developed by 2 companies · 3 clinical trials tracked.
poziotinib evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
What is verified about poziotinib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| Assertio Holdings, Inc. (ASRT) Under investigation for non-small cell lung cancer tumors wi… | Phase 2 |
| SPECTRUM PHARMACEUTICALS INC (SPPI) | Phase 3 |
Clinical Trials (3)
A Randomized, Phase 3 Study of Poziotinib in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring HER2 Exon 20 Mutations (PINNACLE)
Primary endpoint: Progression Free Survival (PFS)
A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)
Primary endpoint: Objective Response Rate (ORR)
A Phase II Study of Poziotinib in EGFR or HER2 Mutant Advanced Solid Tumors
Primary endpoint: Objective response rate a in patients with estimated glomerular filtration rate (EGFR) exon 20 mutant non-small Cell Lung Cancer (NSCLC) (Cohort 1)
Frequently asked questions
Who is developing poziotinib?
poziotinib is being developed by Assertio Holdings, Inc., SPECTRUM PHARMACEUTICALS INC.
How many clinical trials involve poziotinib?
BioSniper tracks 3 clinical trials involving poziotinib.